Oculus Innovative Sciences' CEO and Founder Hoji Alimi Featured on NASDAQ CEO Signature...

* Reuters is not responsible for the content in this press release.

Thu Apr 17, 2008 8:08am EDT 

Oculus Innovative Sciences' CEO and Founder Hoji Alimi Featured on NASDAQ CEO Signature Series

PETALUMA, Calif.--(Business Wire)--
Oculus Innovative Sciences (Nasdaq:OCLS) announced that its CEO
and founder, Hoji Alimi, was today's featured guest on the NASDAQ CEO
Signature Series webcast hosted by financial reporter, Sasha Salama.
In the interview, Mr. Alimi discussed the company's recent milestones
including positive results from the U.S. Phase II clinical study of
Microcyn(R) Technology in patients with mildly infected diabetic foot
ulcers; the approval of Microcyn by China's State Food and Drug
Administration (SFDA); and the company's global commercialization
efforts.

   The webcast can be accessed at http://www.oculusis.com/ceo/ or by
visiting Thomson StreetEvents, FactSet CallStreet, vcall.com and
InvestorCalendar.com.

   About Oculus

   Oculus Innovative Sciences is a biopharmaceutical company that
develops, manufactures and markets a family of products based upon the
Microcyn(R) Technology platform, which is intended to help prevent and
treat infections in chronic and acute wounds. The Microcyn Technology
platform is a biocompatible, shelf-stable solution containing active
oxychlorine compounds that is currently commercialized outside the
United States for the treatment of infected wounds. The solutions
derived from the Microcyn Technology platform have demonstrated, in a
variety of research and investigational studies, the ability to treat
a wide range of pathogens, including antibiotic-resistant strains of
bacteria (including MRSA and VRE), viruses, fungi and spores.

   The technology has also demonstrated wound healing in chronic and
acute wounds in clinical investigational studies. A recently completed
U.S. Phase II clinical trial of Microcyn Technology met the primary
endpoints of safety and efficacy for the treatment of mildly infected
diabetic foot ulcers.

   Oculus' principal operations are in Petaluma, California, and it
conducts operations in Europe, Latin America and Japan through its
wholly owned subsidiaries, Oculus Innovative Sciences Netherlands
B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan
K.K. Oculus' website is www.oculusis.com.

   Oculus and Microcyn are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service
marks are the property of their respective owners.

Oculus Innovative Sciences, Inc.
Dan McFadden, Director of Public and Investor Relations
425-753-2105
dmcfadden@oculusis.com
or
The Ruth Group
Investors:
Sara Ephraim, 646-536-7002
sephraim@theruthgroup.com
or
Media:
Jason Rando / Janine McCargo, 646-536-7025 / 7033
jrando@theruthgroup.com
jmccargo@theruthgroup.com

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.